Evidence map›Paper›PMID 28459416›Full record

ArticleJournal of psychiatry & neuroscience : JPN2017

Age-related brain structural alterations as an intermediate phenotype of psychosis.

Juergen Dukart, Renata Smieskova, Fabienne Harrisberger, Claudia Lenz, André Schmidt, Anna Walter, Christian Huber, Anita Riecher-Rössler, Andor Simon, Undine E Lang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychiatry & neuroscience : JPN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The neurobiology of transition to psychosis: clearing the cache.Journal of psychiatry & neuroscience : JPN · 2017
    Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Juergen DukartFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Renata SmieskovaFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Fabienne HarrisbergerFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Claudia LenzFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
André SchmidtFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Anna WalterFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Christian HuberFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Anita Riecher-RösslerFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Andor SimonFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Undine E LangFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Paolo Fusar-PoliFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).
Stefan BorgwardtFrom the F. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland (Dukart); the Department of Psychiatry (UPK), University of Basel, Basel, Switzerland (Dukart, Smieskova, Lenz, Schmidt, Walter, Huber, Riecher-Rössler, Lang, Borgwardt); the University Hospital of Psychiatry, University Hospital of Bern, Bern, Switzerland, and Specialized Early Psychosis Outpatient Service for Adolescents and Young Adults, Department of Psychiatry, Bruderholz, Switzerland (Simon); and the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience IoPPN), King's College London, London, UK (Schmidt, Borgwardt).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is only limited agreement with respect to location, directionality and functional implications of brain structural alterations observed in patients with schizophrenia. Additionally, their link to occurrence of psychotic symptoms remains unclear. A viable way of addressing these questions is to examine populations in an at-risk mental state (ARMS) before the transition to psychosis.

methodsWe tested for structural brain alterations in individuals in an ARMS compared with healthy controls and patients with first-episode psychosis (FEP) using voxel-based morphometry and measures of cortical thickness. Furthermore, we evaluated if these alterations were modified by age and whether they were linked to the observed clinical symptoms.

resultsOur sample included 59 individuals with ARMS, 26 healthy controls and 59 patients with FEP. We found increased grey matter volume and cortical thickness in individuals with ARMS and a similar pattern of structural alterations in patients with FEP. We further found stronger age-related reductions in grey matter volume and cortical thickness in both patients with FEP and individuals with ARMS, linking these alterations to observed clinical symptoms. LIMITATIONS: The ARMS group comprised subgroups with heterogeneous levels of psychosis risk and medication status. Furthermore, the cross-sectional nature of our study and the reduced number of older patients limit conclusions with respect to observed interactions with age.

conclusionOur findings on consistent structural alterations in individuals with ARMS and patients with FEP and their link to clinical symptoms have major implications for understanding their time of occurrence and relevance to psychotic symptoms. Interactions with age found for these alterations may explain the heterogeneity of findings reported in the literature.

Indexed as

AdolescentAdultAgingBrainCohort StudiesCross-Sectional StudiesFemaleGray MatterHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleOrgan SizePhenotypePsychotic DisordersRisk

Identifiers

PMID28459416
PMCPMC5573573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.